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Most cancerous lesions of the uterine cervix are linked to persistent infections with human papillomaviruses (HPV), most
notably HPV-16 or -18. Vaccine-induced immune responses to the HPV early antigens E6 and E7, which contribute to cell
transformation and are thus expressed in these cervical cancers, could potentially eradicate malignant cells. We generated
recombinant vaccines based on E1-deleted adenovirus human strain 5 or on vaccinia virus strain Copenhagen expressing
either the E6 or E7 oncoproteins of HPV-16. The different vaccines were compared in two experimental mouse tumor models
employing Balb/c or C57Bl/6 mice. Data presented here demonstrate that depending on the model either CD41 or CD81 T
cells provide protection to tumor cell challenge, resulting in striking differences in the efficacy of the four vaccines under
investigation. © 2000 Academic Press
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Vaccination is the most effective medical intervention
to reduce morbidity and mortality to infectious diseases.
Most infections are treated preventatively with vaccines
that provide specific B and T cell-mediated protection to
subsequent encounters with the same pathogen. The
development of efficacious vaccines for treatment or
prevention of cancer has been less successful, due in
part to a lack of well-defined tumor-specific antigens.
The majority of cervical cancers, the second most com-
mon cause of malignancies in women worldwide, are
associated with genital infections by human papilloma-
viruses (HPV) which might provide highly suitable targets
for immunological intervention.
In humans, more than 80 types of the papillomavirus
have been identified to date, some of which are associ-
ated with benign skin abnormalities while others are
found predominantly in anogenital lesions. While some
of the latter cause relatively harmless, although bother-
some, growths, and others are associated with severe
cervical intraepithelial neoplasia (CIN) and invasive can-
cer of the cervix (Zur Hausen, 1991). The most prevalent
of those linked with genital malignancies are HPV-16 and
-18 (Van den Brule et al., 1993) whose DNA, depending
on the method employed, can be detected in more than
20% of sexually active, asymptotic women in the United
States. The high prevalence of these viruses and their
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146association with more than 90% of CIN and invasive
cervical cancer, which despite preventative screening
has a .10,000 new cases per year incidence rate in the
United States, would make a vaccine for HPV-16 or -18
exceedingly useful as a therapy for minimizing residual
disease following surgery or for eradication of precan-
cerous localized lesions.
The DNA of HPV-16 has been fully sequenced and the
putative open-reading frames for the early (E1, 2, 4–7)
and late (L1 and L2) gene products have been identified
(Halbert and Galloway, 1988; Seedorf et al., 1985). Two of
the early gene products, E6 and E7, have transforming
activity. The E7 protein binds to the retinoblastoma sus-
ceptibility gene product (Dyson et al., 1989) while the E6
rotein interacts with the p53 tumor suppressor protein
Werness et al., 1990). Both viral proteins are expressed
n malignant cells (Schwartz et al., 1985). Most HPV types
ncluding HPV-16 cannot readily be propagated in vitro. A
imited amount of virus can be gained from organotypic
ultures (Cameron et al., 1992) or athymic mouse models
Kreider et al., 1985; Bonnez et al., 1998), thus limiting the
uantity of infectious virus for immunological studies.
apillomaviruses are specific; thus no natural animal
odel is available for testing vaccines to HPV. Immune
esponses to papillomaviruses have been studied in
heir mammalian hosts using bovine papillomaviruses
BPV) (Yang et al., 1985), cottontail rabbit papillomavirus
CRPV) (Christensen et al., 1991) which produces tran-
ient or progressive lesions in domestic rabbits, and
anine oral papillomavirus (COPV) (Meyers et al., 1997;
undberg and O’Banion, 1989). Immune responses to
PV have been studied in mice and rats using cell lines
ransfected with vectors expressing HPV early antigens
Borysiewicz et al., 1996; Lin et al., 1996). Results from
these studies suggest that the E6 and E7 oncoproteins
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147VACCINES TO E6 AND E7 ANTIGENSmight serve as antigens for immunotherapy of HPV-
associated cancers.
In this report we compare the efficacy of two different
vaccine carriers in two different mouse strains, Balb/c
and C57Bl/6 mice, for protection against challenge with
HPV-16-induced cancer cells. The vaccines are based on
replication-defective E1-deleted adenovirus human
strain 5 or on vaccinia virus train Copenhagen express-
ing either the E6 or the E7 protein of HPV-16. Our results
show a striking difference in the two mouse models with
respect to both the efficacy of the different vaccines and
to the role of the different T cell populations in limiting
the growth of the tumors.
RESULTS
Characterization of HPV-16-associated tumor cell
lines. The TC-1 cell originated from lung endothelial cells
transformed first by transfection with a retroviral vector
TABLE 1
E6 and E7 Transcript Expression in HPV-16-Associated
Tumor Cell Lines
Cell line Amplicon mRNA concentration (pg/ng)a
t(10)1rasE7E6 E6 0.37
TC-1 E6 2.39
t(10)1rasE7E6 E7 0.15
TC-1 E7 1.97
t(10)1rasE7E6 b-actin 0.075
TC-1 b-actin 0.052
Note. Total RNA was extracted from semiconfluent cells and quan-
titated by spectrophotometry. One hundred nanograms of total RNA
was used for each real-time RT-PCR reaction. b-actin primers were
tilized to control for RNA loading.
a mRNA concentration is calculated as pg mRNA/ng total RNA.
FIG. 1. Surface expression of MHC class I molecules by target murin
class I molecules: H-2KbDb, H-2Kd, and H-2Ld followed by detection with
ere analyzed for fluorescence by flow cytometry. (A) TC-1 cells stai
molecules (solid line). (B) (10)1 cells stained with secondary antibody ontained for H-2Ld molecules (dashed line). (C) t(10)1rasE7E6 cells stained with s
molecules (solid line); t(10)1rasE7E6 cells stained for H-2Ld molecules (dasheexpressing E6 and E7 and then further transduced with a
vector expressing activated human c-ras. This cell line
has been used by others to assess the efficacy of vac-
cines to HPV-16 oncoproteins (Lin et al., 1996; Ji et al.,
1998). The t(10)1rasE7E6 cell line was generated by
transfection of (10)1 cells, an embryonic fibroblast line of
Balb/c origin that spontaneously immortalized by a loss
of both p53 alleles (Harvey and Levine, 1991), with a
triple promoter retroviral vector expressing v-Ha-ras, E6,
and E7 of HPV-16 (Overell et al., 1988). The level of
transcript expression in t(10)1rasE7E6 cells was com-
pared with that of TC-1 cells by quantitative RT-PCR
analysis. Transcripts for E6 and E7 could be detected in
both cell populations. The TC-1 cell line expressed ;9
times more E6 and 20 times more E7 message com-
pared to the t(10)1rasE7E6 cell line (Table 1). Cell lines
were furthermore tested for expression of MHC class I
determinants by indirect immunofluorescence using
mAbs to Kd (SF11.1.1) and Ld (28-14-8) determinants for
(10)1rasE7E6 and mAb to KbDd (28-8-6) determinants for
C-1 (Fig. 1). H-2 Kd molecules could readily be demon-
trated on t(10)1rasE7E6 cells while Ld determinants
were not detectable. The parental (10)1 cell line showed
a similar pattern. A greater amount of H-2 KbDb mole-
cules could readily be shown on TC-1 cells as demon-
strated by immunofluorescence (Fig. 1) which was con-
firmed by staining with mAbs specific for each determi-
nant individually (data not shown). Although these
experiments which used different antibodies to measure
MHC class I expression on the two tumor cell lines did
not allow a direct comparison of the amount of serolog-
ically detectable MHC class I determinants, the data
nevertheless indicate that the TC-1 cell line expresses
higher levels of these molecules compared to
t(10)1rasE7E6 cells.
ines. Cells (5 3 105) were incubated with antibodies specific for MHC
abeled goat and anti-mouse IgG secondary antibody. The stained cells
th secondary antibody only (shaded); TC-1 cells stained for H-2KbDb
ded); (10)1 cells stained for H-2Kd molecules (solid line), and (10)1 cellse cell l
FITC-l
ned wi
ly (shaecondary antibody only (shaded); t(10)1rasE7E6 cells stained for H-2Kd
d line).
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148 HE ET AL.Induction of protective immunity to HPV-16 E6- and
E7-expressing tumors by viral recombinant vaccines. In
the first series of experiments, the efficacy of the two
types of viral recombinants (the vaccina versus the E1-
deleted adenoviral recombinants, expressing E7 or E6 of
HPV-16) was compared in two mouse strains (Balb/c
which are of the H-2d haplotype and C57Bl/6 which are
-2b). C57Bl/6 mice were challenged with syngeneic
C-1 cells, while Balb/c mice were challenged with
(10)1rasE7E6 cells. Groups of 8–10 mice were immu-
ized subcutaneously (sc) with 1–2 3 107 PFU of either of
the viral recombinants. Control mice were injected with
an equal dose of a control construct expressing the
glycoprotein of rabies virus. Two weeks later mice were
challenged sc with tumors cells and tumor development
was recorded. A low percentage of mice failed to de-
velop primary lesions at the site of injection but instead
showed symptoms of metastatic disease. These mice
were euthanized and autopsied.
Balb/c mice, as shown in Fig. 2A, were partially pro-
tected by all of the four vaccines with the AdE7 recom-
binant being the least efficacious, not causing statisti-
cally significant levels of protection. The AdE6 and VacE7
were the most efficacious vaccines with regard to com-
plete protection against tumor development and delay in
onset of tumors in mice that were not completely pro-
tected. In C57Bl/6 mice the results were strikingly differ-
ent (Fig. 2B). None of the vaccinia recombinants nor the
AdE6 recombinants induce any protection to tumor chal-
lenge, while the AdE7 vaccine completely protected 60%
of mice in this experiment and significantly delayed on-
set of lesions in the other 40% of mice.
The different vaccines were next tested in Balb/c mice
for induction of protective immunity to an increased dose
of 5 3 105 t(10)1rasE7E6 tumor cells. All of the mice,
espite vaccination, developed tumors, indicating that
he vaccine-induced immune response could only cope
ith a limited number of tumor cells (data not shown). In
ubsequent experiments, E6- and E7-immune Balb/c
ice that remained disease free after challenge with a
ow dose (3 3 104) of t(10)1rasE7E6 cells were pooled
and rechallenged 3–4 months later with a high dose 5 3
105 of t(10)1rasE7E6 cells. Approximately 80% of the
mmune mice remained tumor free after this severe chal-
enge, which rapidly induced tumors in all of the age-
atched control mice (data not shown), suggesting that
he original tumor cell challenge had boosted the vac-
ine-induced immune response.
The AdE7 vaccine was tested for induction of protec-
ion against increased doses of TC-1 cells. In this exper-
ment, groups of 5 C57Bl/6 mice were immunized with
–2 3 107 PFU of AdE7 or Adrab.gp virus. They were
challenged 2 weeks later with TC-1 cells ranging from
2 3 105 to 2 3 106 cells per mouse. In this set of
experiments the vaccine completely protected against 2,
6, or 10 3 105 cells per mouse for the duration of theobservation period (45 days after challenge). While at a
concentration of 2 3 106 cells, 1 out of 5 mice developed
a tumor around Day 32 (Fig. 3A). All of the control mice
developed lesions between Day 8 and Day 20. Mice from
this experiment that were protected against the original
tumor challenge were injected a second time with 106
tumor cells given ;6 weeks after the first challenge (Fig.
3B). Again most of the mice remained resistant while all
of the control mice rapidly developed tumors.
Metastatic lesions can sometimes form during tumor
progression or following surgical procedures to remove
existing tumors. An additional experiment was per-
formed to further test the efficacy of the AdE7 vaccine to
prevent metastatic tumor formation. In this experiment,
two groups of 9 C57Bl/6 mice were vaccinated with
either 1–2 3 107 PFU of AdE7 or Adrab.gp virus. Two
weeks following immunization the mice were separated
into 6 groups (3 mice/group). Each group received one of
three concentrations of TC-1 cells intravenously (iv) (104,
105, or 106). Mice were euthanized 2 weeks after chal-
enge and their lungs were examined for signs of meta-
tatic lesions. All mice but one (lowest cell dose group)
n the control vaccine group (Adrab.gp) were positive for
ung metastases, while only one mouse (highest cell
ose group) vaccinated with AdE7 displayed signs of
ung tumors (Table 2). Similar experiments were carried
ut in AdE6 virus immune Balb/c mice challenged iv with
05 t(10)1rasE7E6 cells; however, only limited protection
was evident upon AdE6 immunization. Three weeks after
challenge, autopsy of immune mice showed fewer and
smaller lung metastasis compared to Adrab.gp-vacci-
nated control mice (data not shown); complete protection
was not achieved.
The immune effector mechanisms that provide protec-
tion to tumor challenge. The immune effector mecha-
nisms that provide protection to tumor challenge were
elucidated in both systems upon immunization of mice
with the most efficacious vaccines, i.e., the AdE6 recom-
binant for challenge of Balb/c mice with t(10)1rasE7E6
cells and the AdE7 recombinant for challenge of C57Bl/6
mice with TC-1 cells. The immune effector mechanisms
were analyzed in vivo using antibody-mediated depletion
for the Balb/c model and knockout mice as well as
antibody depletion for the C57Bl/6 model.
In Balb/c mice vaccinated with the AdE6 virus or with
a control virus (Adrab.gp), depletion of CD41 cells com-
letely abrogated vaccine-induced protection and accel-
rated development of tumors (Fig. 4). Depletion of CD81
T cells just prior to tumor challenge did not reduce the
degree of protection to challenge with t(10)1rasE7E6
cells, suggesting that in vivo growth of these tumor cells
as limited by T cells of the CD41 rather than the CD81
subset.
In mice of the C57Bl/6 background immunized with theAdE7 recombinant, b2KO mice which lack MHC class I
expression and thus lack functionally active CD81 T cells
149VACCINES TO E6 AND E7 ANTIGENSFIG. 2. Efficacy of the different vaccines in protecting mice against challenge with an HPV-16 E6/E7-expressing tumor. The graph summarizes a
series of experiments. (A) Groups of 8–10 female Balb/c mice were immunized with 1–2 3 107 PFU of either VacE7 or VacE6 virus using the VRG
recombinant as a control. Other groups of mice were immunized with the same dose of AdE7 or AdE6 virus using Adrab.gp virus as a control. Virus
(diluted in saline) was injected once sc into the flank. Mice were challenged 2 weeks later with 3 3 104 t(10)1rasE7E6 cells given sc. Tumor growth
was recorded over a period of 75–100 days. Mice that had tumors of at least 2 mm in diameter were scored as positive. (B) Groups of 8–10 C57Bl/6
mice were immunized with 1–2 3 107 PFU of virus as described in the legend of Fig. 2A. Two weeks after vaccination mice were challenged with
2 3 105 TC-1 cells given sc. (n ) Mice immunized with the vaccine to HPV-16; (h) mice immunized with the control vaccine. The numbers in brackets
reflect the statistical significance.
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150 HE ET AL.(Zijlstra et al., 1990) showed an increased natural resis-
ance to TC-1 challenge. About one-third of the b2KO
mice vaccinated with the Adrab.gp construct survived
challenge with a dose of TC-1 cells that caused tumor
formation in all of the Adrab.gp-vaccinated C57Bl/6 mice
(Fig. 5). AdE7 vaccination, which protected all of the
FIG. 3. The AdE7 vaccine induced protection to challenge with differ
1–2 3 107 PFU of AdE7 or Adrab.gp virus. Mice were challenged 2 we
was recorded over a period of 45 days. (B) AdE7-immune mice that su
injected with 1 3 106 TC-1 cells given to the preimmune mice 6 weeks
f 35 days. ( n ) Mice immunized with the vaccine to HPV-16; (h) mice
TABLE 2
AdE7-Induced Protection against the Formation of Lung Metastasis
upon iv Challenge with TC-1 Cells
No. of TC-1 cells
% Metastasis-free mice/mean lung weight
(mg) 6 SD
Adrab.gp virus AdE7 virus
104 16.7%/167 6 17 100% / 148 6 3.6
105 0% / 178 6 7.1 100% / 150 6 6.8
106 0% / 560 6 57 88.9% / 157 6 22
Note. C57Bl/6 mice were inoculated with control (Adrab.gp) or AdE7
accines and challenged iv 2 weeks later with three different doses of
C-1 cells. Fourteen days postchallenge the lungs were examined
acroscopically for visible tumors and were weighed. The mean 6
tandard deviation per group was calculated. The average lung weight
o
u
f a normal age-matched mouse was determined to be ;148 mg. Data
rom two separate experiments.C57Bl/6 mice, failed to protect any of the b2KO mice
tressing the importance of cytolytic T cells in this animal
odel. CD4KO (Xiang et al., 1995) mice in contrast not
nly showed an increased natural resistance to chal-
enge with TC-1 cells but also showed complete protec-
ion upon AdE7 vaccination, suggesting that T helper
ells did not contribute to the eradication of TC-1 cells.
ith regard to cytokines, lack of IFN-g in GKO mice
Dalton et al., 1993) but not lack of IL-4 in IL-4 KO (Kuhn
t al., 1991) mice strongly reduced the efficacy of the
accine. Knockout mice commonly develop alternate
athways to compensate for the lack of a given immune-
ffector mechanism. Additional challenge experiments
ere conducted using C57Bl/6 mice that had been
reated upon vaccination with the AdE7 or Adrab.gp
onstructs with depleting doses of antibodies to CD4 or
D8 prior and during challenge with TC-1 cells. The
esult of this set of experiments confirmed those ob-
ained in KO mice. Depletion of CD81 cells abrogated
AdE7 vaccine-induced protection while depletion of
CD41 cells had no such effect (Fig. 5).
Vaccine-induced cytolytic T cell responses. To further
nalyze the role of cytolytic T cells in providing clearance
es of tumor cells. (A) Groups of 5 C57Bl/6 mice were vaccinated with
ter with various doses of TC-1 cells given sc. Development of tumors
he first challenge as well as an additional group of control mice were
e initial challenge. Development of tumors was recorded over a period
ized with the control vaccine.ent dos
eks la
rvived tf tumor cells, we tested splenocytes of vaccinated mice
pon in vitro stimulation for cytolysis of syngeneic target
2
o
A
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151VACCINES TO E6 AND E7 ANTIGENScells expressing the appropriate antigen. Mice were vac-
cinated with 1–2 3 107 PFU of AdE7, VacE7, AdE6, or
VacE6 virus. Splenocytes were harvested 7 days later.
Part of the splenocytes were stimulated in vitro under
bulk culture conditions for 5 days, the remainder were
stimulated under limiting dilution conditions for 7 days.
Cells stimulated in bulk culture were tested for their
ability to lyse syngeneic tumor cells. They were also
tested for lysis of unmodified cells (C57SV cells for
C57Bl/6 splenocytes and (10)1 cells for Balb/c spleno-
cytes). To assess HPV-16 E6- or E7-specific lytic activity,
cells from mice vaccinated with the vaccinia virus recom-
binant were tested on target cells infected with the ad-
enoviral recombinant and vice versa. Cells were also
tested on target cells infected with the same construct
used for immunization to measure overall lytic activity
directed against the HPV antigen as well as the antigens
of the vaccine carrier. No E6-specific lysis could be
observed after immunization of Balb/c or C57Bl/6 mice
with either the E6 vaccinia or the E6 adenoviral recom-
binant (data not shown), suggesting that this antigen
lacks an epitope for association with MHC class I deter-
minants expressed by the target cells of either haplotype.
Immunization with E7 expressed by the E1-deleted ade-
novirus caused, in both mouse strains, activation of cy-
tolytic T cells that efficiently lysed syngeneic target cells
infected with the adenoviral recombinant (Fig. 6). In
C57Bl/6 mice the AdE7 virus-induced effector cell popu-
lation also lysed target cells infected with the vaccinia E7
recombinant and, albeit to a lower percentage, TC-1
tumor cells, indicating induction of E7-specific cytolytic T
cells. In Balb/c mice immunization with the AdE7 recom-
binant did not result in a measurable cytolytic T cell
response to target cells expressing E7 following infec-
FIG. 4. The role of different T cell subsets in providing protection to
4 female Balb/c mice were immunized with 1–2 3 107 PFU of Adrab.g
ne group did not receive further treatment, one was injected with a m
ntibody in the form of diluted ascitic fluid was given on Days 14, 16,
fter the vaccination. Mice were treated once a week with an additiona
mmunized with the vaccine to HPV-16; (h) mice immunized with the ction with the heterologous vaccine carrier. This lack of an
HPV-16-specific cytolytic T cell response was not exclu-sively due to low expression of MHC class I determi-
nants on (10)1 or t(10)1rasE7E6 cells (which express
comparable levels of serologically detectable MHC class
I molecules) as (10)1 cells infected by the AdE7 recom-
binant were lysed by AdE7 immune splenocytes presum-
ably by T cells to adenoviral antigens. The vaccinia E7
recombinant induced a cytolytic T cell response in
C57Bl/6 that could be measured on C57SV target cells
infected with AdE7. The response was below detectabil-
ity on TC-1 cells. Balb/c mice mounted a high nonspecific
cytolytic response to immunization with the vaccinia E7
recombinant. An E7-specific cytolytic response could not
be observed.
These results were confirmed using splenocytes stim-
ulated in vitro under limiting dilution conditions (Fig. 7).
Effector cells were tested on two target cells only (tumor
target cells and unmodified syngeneic control cells). The
highest precursor frequency was demonstrated in
C57Bl/6 mice immunized with the AdE7 recombinant
(1:6400) followed by a frequency in VacE7-immunized
C57Bl/6 mice of ;1:11,000 (Fig. 7B). Frequencies in
Balb/c immunized with either construct were below
1:15,000. Furthermore, in Balb/c mice, lysis of unmodified
target cells paralleled those of E7-expressing tumor
cells, indicating that the observed lysis was nonantigen
specific.
The AdE7 recombinant was used for in vitro stimu-
lation of T cells derived from AdE7 and VacE7 virus
immunized mice. Using this approach, which was ne-
cessitated by the cytopathic nature of the vaccinia
virus recombinant, E7-specific T cells from mice inoc-
ulated with the VacE7 construct were thus selectively
expanded. However, both E7 and adenovirus-specific
lymphocytes from AdE7 virus-immune mice were stim-
sE7E6 tumor challenge in AdE6 virus-immune Balb/c mice. Groups of
E6 virus. Fourteen days later, mice were subdivided into three groups:
al antibody to CD8, and the other with a monoclonal antibody to CD4.
ip. Mice were challenged with 3 3 104 t(10)1rasE7E6 cells on Day 26
f antibody to ensure continued depletion of the T cell subset. (n ) Mice
vaccine.t(10)1ra
p or Ad
onoclon
and 18ulated during the in vitro culture, which might have
biased the results, giving a false low frequency for the
r
n
G
c
l TC-1 c
152 HE ET AL.E7-specific response induced in vivo with the AdE7
ecombinant. We therefore employed an additional
ovel detection method for CD81 antigen-specific T
cells based on intracellular cytokine staining of pep-
tide-reactivated CD81 T cells (Murali-Krishna et al.,
1998). Initially, we determined that a peptide carrying a
previously defined sequence of the E7 protein of
HPV-16 (Vierboom et al., 1998) was indeed recognized
by cytolytic T cells of C57Bl/6 mice induced with our
vaccine constructs. In vitro-stimulated splenocytes
from AdE7 virus-immune mice were tested for lysis of
RMAS cells pulsed with either the E7 peptide or an
unrelated peptide, which, similar to the E7 peptide,
induces MHC class I expression on RMAS cells. As
shown in Fig. 8, RMAS target cells pulsed with the E7
FIG. 5. The role of different T cell subsets in providing protection to
roups of 5–8 knockout mice or normal C57Bl/6 mice were vaccinated
2 weeks later with 2 3 105 TC-1 cells and the development of tumors
ompletely resistant to challenge with 2 3 105 TC-1 cells, were injected
with 1–2 3 107 PFU of (h) Adrab.gp or (n ) AdE7 virus and depleted of
eft untreated. Mice were then challenged 2 weeks later with 2 3 105peptide but not with the control peptide were very
efficiently lysed by T cells from AdE7 virus-immune cmice, thus confirming that this peptide is suitable for
activating E7-specific CD81 T cells from C57Bl/6 mice
in vitro.
Intracellular cytokine staining of peptide-pulsed
CD81 T cells, a method which is by far more sensitive
than traditional 51Cr-release assays (Murali-Krishna et
al., 1998), again validated that the adenoviral recom-
binant stimulated a stronger CD81 T cell response to
E7 compared to the vaccinia virus recombinant (Table
3). Approximately 0.7% of CD81 splenocytes from AdE7
virus-immune mice were specific for the E7 peptide
while less than 0.05% of splenocytes from VacE7-
vaccinated mice responded to this peptide. These
results indicate that the replication-defective adenovi-
ral recombinant was more than 10-fold more effica-
1
mor challenge in AdE7 virus-immune C57Bl/6 mice. Upper two rows:
2 3 107 PFU of (n ) AdE7 or (h) Adrab.gp virus. Mice were challenged
corded. CD4KO mice, which even upon Adrab.gp immunization were
3 106 cells. Lower row: Groups of 5–8 C57Bl/6 mice were vaccinated
r CD41 T cells as described in the legend of Fig. 4. Control mice were
ells and tumor growth was recorded.TC-1 tu
with 1–
was re
with 1
CD81 ocious in inducing transgene-specific CD8 T cells
ompared to the replication-competent vaccinia virus
v
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153VACCINES TO E6 AND E7 ANTIGENSrecombinant given at an equal dose. Data obtained
with this technique furthermore confirmed that our in
vitro stimulation method had indeed favored the E7
response induced by the vaccinia virus recombinant.
DISCUSSION
In this study we compared the efficacy of two types of
recombinant viral vaccines, expressing either the E6 or
the E7 protein of HPV-16, for their ability to stimulate an
immune response to eradicate tumor cells transformed
upon transfection with vectors expressing these two on-
coproteins together with activated ras.
Most women infected with HPV-16 or -18 fail to de-
velop cervical cancer. This is presumably due in part to
an immune response to HPV antigens that clears virus-
infected cells as suggested by an increased rate of
cervical cancers in immunosuppressed women (Penn,
1993). Immune responses to HPV have been studied in
HPV-16-infected women as well as in experimental ani-
mals such as mice and rats. In women positive for
FIG. 6. The HPV-16 E6/E7-specific cytolytic T cell response to immuni
ice were vaccinated with 1–2 3 107 PFU of AdE7 or VacE7 given sc.
estimulated for 5 days with 0.1 PFU/cell of AdE7 virus. Effector cells w
negative control), syngeneic cells infected with VacE7 or AdE7, or syng
ells; Balb/c splenocytes were tested on (10)1 and t(10)1rasE7E6 targe
arget cells, and (m) VacE7 infected target cells.HPV-16 lymphoproliferative responses to E6 and E7 were
shown to inversely correlate with the viral load (Kadish et
(
val., 1997). Cytolytic T cells to HPV-16 E6 and E7 were also
demonstrated in the blood of women with HPV-16-asso-
ciated cervical neoplasia, although their relevance in
disease progression remains to be defined (Jochmus et
al., 1997). In experimental models, prevaccination of rats
with vaccinia virus recombinants expressing HPV-16 E6
or E7 resulted in partial protection against a tumor cell
line transformed by the HPV oncoproteins and v-Ha-ras
(Chen et al., 1991). Using a mouse model, immunization
with vaccinia virus recombinant expressing E6 or E7 of
HPV-16 was shown to protect against subsequent chal-
lenge with tumor cells expressing these oncoproteins
(Meneguzzi et al., 1991). In another study in mice a
accinia virus construct expressing a chimeric protein
omposed of E7 linked to the sorting signal of the lyso-
ome-associated membrane protein 1 (LAMP-1), target-
ng the E7 protein toward the MHC class II processing
athway, induced regression in mice carrying small tu-
ors expressing the E7 protein. Regression could not be
chieved with a vaccinia virus expressing wild-type E7
ith the different vaccine constructs. Groups of 3–5 C57Bl/6 and Balb/c
eek later mice were euthanized, and splenocytes were prepared and
ted at varied effector/target cell ratios on unmodified syngeneic cells
mor cells (C57Bl/6 splenocytes were tested on C57SV and TC-1 target
. (µ) Unmodified target cells, (n ) tumor target cells, (h) AdE7 infectedzation w
One w
ere tes
eneic tuLin et al., 1996). Upon vaccination with the chimeric
accinia virus construct, protection depended on both
c
i
while Balb/c splenocytes were tested on t(10)1rasE7E6 and (10)1 cells.
(A) 51Cr release of target cells plotted against the number of responder
154 HE ET AL.CD81 and CD41 T cells. In additional studies, dendritic
ells pulsed with E7 protein or synthetic peptides carry-
ng E7 sequences were found to induce CD81 T cell-
mediated protection against challenge with E7 protein
expressing tumor cells (De Bruijn et al., 1998).
Taken together these data clearly show that the E6
and E7 oncoproteins can induce T cell-mediated immune
responses that at least in experimental animals prevent
or even halt the progression of HPV-16-expressing tumor
cells. Different types of vaccines can be utilized for treat-
ment of cancer. Purified viral proteins induce both anti-
body and T helper cell responses, but generally require
the use of adjuvants and multiple immunizations in order
to achieve a potent immune response. Peptide vaccines
carrying immunodominant T cell epitopes can, upon in-
corporation into liposomes (Fries et al., 1992) or ISCOMS
(Morein, 1998; Tarpey et al., 1996), induce both cytolytic T
cells and T helper cells. Nevertheless, the immune re-
sponse against peptides is genetically controlled by the
ability of the peptide to bind to the MHC groove of a
given haplotype (Ir-gene control; Benacerraf et al., 1972).
Peptide vaccines are thus unsuited for immunization of
an outbred population. Vaccines based on recombinant
viruses (Wiktor et al., 1984) or bacteria (Aldovini et al.,
1991; Poirer et al., 1988) generally induce strong immune
responses including antibodies, T helper cells, and cy-
tolytic T cells. Nevertheless, due to their infectious and
commonly replication-competent nature they can exhibit
unwanted side effects especially in elderly or immuno-
compromised patients.
We have studied the suitability of E1-deleted replica-
tion-defective adenoviral constructs as vaccine carriers
(Xiang et al., 1996). Such constructs initially developed
for gene therapy (Yang et al., 1995, 1996) were found to
induce a potent immune response both to adenoviral
antigens and to the transgene products (Yang et al.,
1995) which limits their usefulness for long-term replace-
ment of missing or faulty genes. The magnitude of the
immune response achieved by the E1-deleted adenoviral
recombinants (also defective in E3 expression and thus
unable to downregulate MHC expression; Ginsberg et
al., 1989) and their inability to replicate, thus not causing
major side effects even when used at excessive doses,
led us to develop such constructs for use as experimen-
tal vaccines. We initially cloned the rabies virus glyco-
cells per well. AdE7 immune C57Bl/6 responder cells tested on TC-1
cells (1A) or C57SV fibroblasts (1B); VacE7 immune C57Bl/6 responder
cells tested on TC-1 cells (2A) or C57SV fibroblasts (2B); AdE7 immune
Balb/c responder cells tested on t(10)1rasE7E6 cells (1a) or on (10)1
fibroblasts (1b); VacE7 immune Balb/c fibroblasts tested on
t(10)1rasE7E6 cells (2a) or on (10)1 fibroblasts (2b). (B) Linear regres-
sion plotting the percentage negative wells against the number of
responder cells per well. Linear regression curves are shown only forFIG. 7. The frequency of tumor-specific cytolytic T cells upon immu-
nization with vaccines to E7. Splenocytes of C57Bl/6 and Balb/c mice
immunized as described in the legend to Fig. 6 were restimulated 7
days after vaccination under limiting dilution conditions using 24 wells
for each responder cell dilution. Seven days later cells of each well
were split in two and tested on two different target cells. C57Bl/6
splenocytes were tested on TC-1 cells and unmodified C57SV cellsthe tumor target cells not for the control target cells. (n ) Mice immu-
nized with AdE7; (m) mice immunized with VacE7.
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155VACCINES TO E6 AND E7 ANTIGENSprotein into an E1-deleted adenovirus human strain 5.
The resulting recombinant (Adrab.gp) induced in mice,
both upon systemic inoculation or upon application to
the mucosal membranes of the airways, a virus-neutral-
izing antibody response to rabies virus that was by far
more potent than that induced by a comparable dose of
a vaccinia virus recombinant expressing the same trans-
gene product (Xiang et al., 1996).
The results from the current study confirm that E1-
deleted adenoviral recombinants also induce a more
potent cytolytic T cell-mediated immune response com-
pared to vaccinia virus recombinants. In C57Bl/6 mice,
the AdE7 vaccine provided, with some experimental vari-
ability, 60–100% protection against challenge with TC-1
tumor cells whereas the vaccinia E7 recombinant in-
duced no protection against the growth of this tumor cell
line. Lack of efficacy of the vaccinia E7 recombinant in
our set of experiments confirms previously published
data also based on TC-1 challenge of C57Bl/6 mice
where only a vaccinia virus recombinant expressing a
chimeric form of the E7 protein linked to the LAMP-1
sorting signal but not the recombinant carrying the wild-
type form induced protection against TC-1 tumor cell
challenge (Lin et al., 1996). Protection upon vaccination
with the AdE7 recombinant depended on CD81 T cells as
well as on IFN-g, a cytokine secreted by both T helper
nd cytolytic T cells as well as by natural killer cells.
D41 T cells or IL-4 were not required to limit the growth
of TC-1 cells. This is in contrast to the previously pub-
lished results obtained with the vaccinia E7-LAMP-1 re-
combinant; in this model protection against tumor cell
challenge required both CD41 and CD81 T cells (Lin et
al., 1996). In vitro cytotoxicity assays using either bulk
FIG. 8. The epitope specificity of E7-specific CD81 T cells of C57Bl/6
origin. Splenocytes from AdE7-immune C57Bl/6 mice were cultured for
5 days in presence of 0.1 PFU of AdE7 virus per cell. Lymphocytes were
then tested at different effector to target cell ratios on RMAS cells
pulsed with ( n ) a peptide from E7 or (h) a peptide from mouse p53.ulture-derived cytolytic T cells or, for a more quantitative
nalysis, T cells reactivated under limiting dilution con-itions or intracellular cytokine staining of peptide-reac-
ivated CD81 T cells showed that in C57Bl/6 mice the
dE7 recombinant induces a strong cytolytic T cell re-
ponse to E7-expressing target cells which is more than
0-fold higher than that induced by the vaccinia virus
ecombinant. We hypothesize that the apparently contra-
ictory results regarding the role of different T cell sub-
ets in providing protection to TC-1 challenge upon vac-
ination with the AdE7 or the vaccinia E7-LAMP-1 recom-
inant might be a reflection of the magnitude of the
accine-induced cytolytic T cell response. A strong cyto-
ytic T cell response, such as the one induced by the
dE7 recombinant, might suffice to eradicate the TC-1
ells. A more moderate response might require addi-
ional input from CD41 T cells, which alone are insuffi-
cient to completely eliminate the transformed cells. In
C57Bl/6 mice, neither of the E6-expressing recombinant
vaccines induced a cytolytic T cell response to the
HPV-16 oncoprotein nor protection to TC-1 challenge.
Results obtained in our second mouse model based
on t(10)1rasE7E6 cells were in stark contrast to those
obtained in the TC-1 model. Balb/c mice could be par-
tially protected (less than 50% complete protection and
delay of onset of tumors) by all of the four vaccines
expressing either the E6 or the E7 protein; however,
protection achieved by the AdE7 vaccine was marginal
and statistically not significant. Mice-generated cytolytic
T cells to neither of the HPV-16 oncoproteins as pre-
sented by the recombinant vaccines and accordingly
protection tested upon vaccination with one of the best
vaccines, the AdE6 recombinant, depended on CD41T
cells; depletion of CD81 T cells did not abrogate the
ffect of the vaccine. None of the vaccines resulted in
omplete protection of Balb/c mice in any of the exper-
ments using very limited doses of tumor cells. These
esults indicate that a potent CD81 T cell response, such
s the one induced by the AdE7 vaccine in C57Bl/6 mice,
s best suited to eradicate HPV-16 early protein-express-
ng tumor cells. However, considering the differences
TABLE 3
The Frequency of E7-Specific CD81, IFN-g-secreting T cells upon
Immunization of C57Bl/6 Mice with AdE7 or VacE7 Virus
Vaccine In vitro Antigen % IFN-g1/% CD81
AdE7 p53 peptide 0.032
AdE7 E7 peptide 0.75
VacE7 p53 peptide 0.036
VacE7 E7 peptide 0.08
Note. Splenocytes from C57Bl/6 mice immunized 7 days previously
with AdE7 or VacE7 virus were restimulated in vitro for 5 h with the E7
peptide or a control peptide from mouse p53. Cells were then stained
for CD8 using a PE-labeled antibody and for intracellular IFN-g using
an FITC-labeled antibody and analyzed by FACS. The percentage of
cells that stained for both of the two dyes versus percentage of CD81
cells is shown.
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156 HE ET AL.between the two tumor models other explanations re-
main to be considered.
In both models, vaccinated mice challenged with tu-
mor cells remained resistant to further tumor challenges
given weeks or even months later. In the case of Balb/c
mice that could only be protected by vaccination against
a fairly small dose of tumor cells (;3 3 104), the tumor
cells apparently boosted the vaccine-induced immune
response as mice that survived the initial challenge be-
came resistant to injection with higher doses of tumor
cells. It remains to be investigated if this enhanced
immunity upon challenge is caused by CD41 or CD81 T
ells.
The contrasting efficacy of the different vaccines and
he opposing role of CD41 versus CD81 cells in provid-
ng protection to tumor challenge in the two models
resented here might reflect a genetic difference of the
wo mouse strains. The E6 and E7 oncoproteins are both
airly small antigens (159 and 123 amino acids, respec-
ively) and it is feasible that the E6 protein lacks an
pitope for association to MHC class I determinants of
he H-2b or H-2d haplotype while the E7 protein carries a
trong epitope for H-2b, as has already been demon-
strated by the use of synthetic peptides (Vierboom et al.,
1998), but has no sequence for binding to H-2d MHC
lass I determinants. Conversely, neither protein might
nduce a strong T helper cell response in C57Bl/6 mice
ue to the absence of an immunodominant epitope for
-2b MHC class II binding while such epitopes may be
present for the H-2d haplotype. Previous studies have
shown that vaccines which express a form of E7 that is
channeled into the lysosomal pathway can induce CD41
T cell-dependent protection to tumor challenge in
C57Bl/6 mice, indicating that this protein carries a pre-
sumably subdominant T helper cell epitope for associa-
tion to H-2b (Lin et al., 1996). It is likely that the genetic
background of the two different mouse strains also af-
fects the vaccine efficacy. For example Balb/c mice have
a defect in their IL-12 receptor signaling pathway (Guller
et al., 1995) and are thus more prone to develop Th2
responses that might not favor optimal activation of cy-
tolytic T cell responses. A third factor which might con-
tribute to the contrasting results is that the two tumor cell
lines express different amounts of E6 and E7 antigens.
TC-1 cells, as tested at the level of transcripts, express
;10–20 times more E6 and E7 compared to
t(10)1rasE7E6 cells. This most likely reflects that the TC-1
cell was generated by transfection with two retroviral
vectors, one expressing E6/E7 and the other activated
ras, while the t(10)1rasE7E6 cell line was produced by
transfection with a triple promoter retroviral vector which
only achieves low expression of the coding sequences
that are farther downstream. Furthermore, t(10)1rasE7E6
cells as well as the parental (10)1 cell line express lower
levels of serologically detectable MHC class I determi-
nants. Although these amounts are adequate to allow
p
flysis by T cells specific for adenoviral antigens, as shown
in Fig. 6, they might not suffice for efficacious presenta-
tion of less abundant CD81 T cell epitopes such as those
erived from E7 or E6. The antigen’s cell surface density
ay affect the role of different immune effector mecha-
isms. The impressive protection to TC-1 cells observed
fter AdE7 or the vaccinia E7/LAMP-1 recombinant vac-
ination might thus reflect an unduly optimistic picture
or patients with HPV-16-associated cancer cells ex-
ressing more discreet levels of these two oncoproteins.
owever, this remains to be investigated further by test-
ng additional HPV-16-induced tumor cell lines with high/
ow levels of transgene expression in Balb/c and C57Bl/6
ice, respectively.
MATERIALS AND METHODS
nimals
Female C57Bl/6, Balb/c and interferon-knockout (GKO)
ice were purchased from Jackson Laboratory, Bar Har-
or, Maine. Mice were housed at The Animal Facility of
he Wistar Institute. They were used at 2–3 months of
ge. CD4, b2, and IL-4 knockout mice were bread at The
Animal Facility of The Wistar Institute. Rats, used as a
source of cytokines, were purchased from Harlane
Sprague Dowley and used at 3 months of age.
Expression systems for E6 and E7 of HPV-16
a. Retroviral vectors. A triple promoter retroviral con-
struct expressing v-Ha-ras under the control of the long-
terminal repeat, E7 under the SV40 promoter, and E6
under the HSVtk promoter was generated from the
plRMtkneo vector (Wang et al., 1991). This plasmid,
ermed plRMtkrasE7E6, was constructed as follows:
plRMtkneo was cut with HindIII to remove the v-ras
oding sequence, the SV40 promoter, and the v-myc
ragment. A fragment containing the v-ras sequence, the
V40 promoter, and the v-myc fragment. A fragment con-
aining the v-ras sequence, the SV40 promoter, and the
7 coding sequence was excised from the pJRrasE7
ector (Wang et al., 1991) by HindIII digestion and ligated
nto the HindIII-digested plRMtkneo vector backbone.
he new construct was digested with MluI and ClaI to
remove the neo coding sequence. The E6 open-reading
frame, excised from the pBlue.E6 vector generated orig-
inally from the E6 open-reading frame of the
pBR322HPV-16 vector, (Seedorf et al., 1985), was cloned
into the vector by blunt-end ligation.
b. Vaccinia virus recombinants expressing E6 or E7.
The E6 coding sequence was excised from the pBlue.E6
vector by digestion with KpnI. The fragment was cloned
into the KpnI site of the pSC11 vector (Charabarti et al.,
985). The E7 open-reading frame was excised from the
Blue.E7 vector (generated from the E7 open-reading
rame of the pBR322HPV-16 vector; Seedorf et al., 1985)
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157VACCINES TO E6 AND E7 ANTIGENSby digestion with SstII and ApaII and ligated into the
same sites of the pSC11 vector. Transfer vectors with the
E6 or E7 in correct orientation to the early/late vaccinia
virus H6 promoter were transfected into Vero cells that
had previously been infected with 0.1 PFU of vaccinia
virus strain Copenhagen. Tk2 virus was obtained by
rowing virus obtained from Vero cells in presence of
rifluorothymidine on Tk2143B cells (Perkus et al., 1898).
Recombinant viral plaques were isolated upon staining
for b-galactosidse expression and subjected to two
ounds of plaque purification. Recombinant viruses were,
n addition, characterized by reverse-transcription poly-
erase chain reaction (RT-PCR) of total RNA from in-
ected cells using E6- or E7-specific primers. A vaccinia
irus expressing the glycoprotein of rabies virus, termed
RG (Wiktor et al., 1984), was used as a control.
c. Adenovirus recombinants expressing E6 or E7. The
6 sequence was excised from the pBlue.E6 vector by
igestion with XhoI and NotI and cloned by blunt-end
igation into the NotI site of the pAdCMVlacZ transfer
ector (Xiang et al., 1996). The E7 fragment was excised
rom the pBlue.E7 vector by NotI and XhoI digestion and
lunt-ended into the NotI site of the pAdCMVlacZ vector.
urified adenoviral DNA human strain 5 was cut with
laI to remove the left end of the viral genome. E1-
ransfected 293 cells (Graham et al., 1977) were cotrans-
ected with the cut adenoviral DNA and linearized trans-
er vector with the E6 or the E7 sequence in correct
rientation to the CMV promoter. Plaques were selected,
ested for presence of E6 or E7 sequences by PCR, and
hen subcloned twice more to obtain recombinant virus
ree of wild-type virus contamination. An E1-deleted ad-
noviral recombinant expressing the glycoprotein of ra-
ies virus was used as a control. The control recombi-
ant, termed Adrab.gp, has been described previously
Xiang et al., 1996).
ell lines
The following cell lines were used throughout the
xperiments: Tk2143B cells were used for propagation of
vaccinia virus and 293 cells, transfected with E1 of ade-
novirus human strain 5, were used for propagation of
adenovirus. The TC-1 cell line (most kindly provided by
T. C. Wu, John Hopkins, Baltimore, MD) expresses both
the E6 and E7 proteins of HPV-16 and forms solid tumors
upon inoculation into mice (Lin et al., 1996). This line was
used to test vaccines in the C57Bl/6 mouse strain. The
(10)1 cell line (most kindly provided by A. L. Harvey),
which is a Balb/c fibroblast line that spontaneously im-
mortalized due to the loss of both p53 alleles, was used
to generate an E6- and E7-expressing tumor cell line that
grows in Balb/c mice. This was achieved by transfecting
(10)1 cells with the plRMtkrasE7E6 vector using calciumrecipitation. Several days later, transfected cells (with-
ut any prior selection) were injected subcutaneouslynto several nude Balb/c mice. These mice developed
umors after 2–3 months. Tumors were excised, single
ells were prepared, and a stable cell line was estab-
ished. This cell line was shown, both by immunofluores-
ence using antibodies to E6 and E7 (most kindly pro-
ided by L. Gissmann) and by RT-PCR, to express the two
ncoproteins. Cells were injected into normal Balb/c
ice where they formed solid tumors within 2–3 weeks.
gain, a cell line was established and shown to express
oth E6 and E7 (this line was termed t(10)1rasE7E6). The
ell line, upon subcloning, was used for further studies.
dose response curve was established to determine the
umber of cells that produced tumors in Balb/c mice-
noculated sites. A dose of 3–5 3 104 cells was found to
result in formation of solid tumors in all of the mice after
2–3 weeks following inoculation. The C57SV cell line,
which was derived by transforming C57Bl/6 fibroblasts
with SV40 (most kindly provided by B. Knowles, Jackson
Laboratory), and the TAP-deficient RMAS line (donated
by H. Ploegh, Harvard Medical School, Boston, MA) were
used as a target cells for cytolytic T cell assays. Culture
supernatant from the hybridoma lines 28-14-8 (ATCC,
anti-Ld) and SF11.1.1 (ATCC, anti-Kd) were used to char-
cterize the t(10)1rasE7E6 cell line. All of the above
escribed cell lines were grown in Dulbecco’s modified
agle’s medium supplemented with 10% FBS, HEPES
uffer, and antibiotics.
ynthetic peptide
The E7 peptide RAHYNIVTF (Vierboom et al., 1998) and
control peptide delineated from mouse p53 VMCYSPPL
Vierboom et al., 1997), which also binds MHC class I
eterminants of the H-2b haplotype, were synthesized by
the Peptide Facility of the Wistar Institute. The peptides
were purified by high-pressure liquid chromatography;
their sequence was verified by mass spectroscopy.
Indirect immunofluorescence
Cells (0.5–1 3 106 per sample) were incubated for 45
in at 4°C with 100 ml of hybridoma supernatant or a
:200 dilution of a commercially available antibody to
HC class I. Control cells were incubated with medium.
ells were washed twice with PBS and then incubated
or 45 min with 30 ml of a 1:20 dilution of an FITC-labeled
goat anti-mouse Ig (Cappel, Organon Teknika Corp.).
Cells were washed twice with PBS, resuspended in 500
ml of PBS and analyzed by flow cytometry. Antibodies
28-8-6 (anti KbDb) and AF6-88-5 (anti Kb) were tested on
C-1 cells; SF11.1.1. to Kd and 28-14-8 to Ld were tested on
(10)1 and t(10)1rasE7E6 cells.
Polymerase chain reaction and reverse transcription
PCRThe presence of E6 and E7 sequences was demon-
strated using a PCR or RT-PCR with the following prim-
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158 HE ET AL.ers: E6 forward primer, ACAGGAGCGACCCAGAAAGT-
TAC; E6 reverse primer, CAGCTGGGTTTCTCTACGTGT-
TCTTG; length of amplified fragment, 476 bp; E7 forward
primer, GCAACCAGAGACAACTGATC; E7 reverse
primer, GGTCTTCCAAAGTACGAATG; length of ampli-
fied fragment; 296 bp. The RT portion of the RT-PCR
was conducted using SuperScript reverse transcrip-
tase (Gibco/BRL) at 50°C (10 min). The PCR cycling
was conducted with Taq polymerase for both se-
uences at 94°C (3 min), 50°C (1 min), and 72°C (1
in) for 30–40 cycles.
eal-time quantitative RT-PCR
Total RNA was extracted from confluent cells grown in
0-mm dishes or from excised frozen tumor tissue ac-
ording to the protocol included with the Ultraspec RNA
olution system kit (Biotex, Houston, TX). Tumor tissues
ere homogenized using a hand-held glass-Teflon ho-
ogenizer prior to RNA purification. RNA was resus-
ended in DEPC-treated d-H2O and quantitated by spec-
rophotometry.
The RT-PCR was prepared using the LightCycler-RNA
mplification kit SYBR Green I (Boehringher Mannheim,
ndianapolis, IN). Briefly, a master mix was prepared
ccording to the included protocol for each set of prim-
rs (cytokine, HPV-16 E6, E7, and b-actin). Nineteen mi-
roliters of master mix was transferred to a precooled
ightCycler capillary tube for each sample. One microli-
er of total RNA (100 ng/ml) was added to each capillary
1 ml of d-H2O was used as a negative control). Capillar-
ies were capped and centrifuged briefly. Capillaries were
transferred to the rotor of the LightCyler instrument and
cycle parameters set according to the optimized guide-
lines included with the kit. Primer annealing temperature
was set at 52°C while the elongation segment was set
for 20 s (based upon the length of the E6 PCR product).
Following the RT-PCR, the data were analyzed utilizing
the software (quantification program) included with the
LightCycler. Cytokine mRNA standards (LightCycler con-
trol kit RNA) were used to determine a logarithmic scale
to which unknown concentrations could be determined.
Propagation and purification of viruses
Vaccinia virus and vaccinia virus recombinants were
grown on confluent monolayers of Tk2 cells infected with
0.1 PFU/cell of virus. Cells were harvested after 48 h and
freeze/thawed three times. Cell debris was removed by
centrifugation at 2000 rpm for 30 min. For some experi-
ments virus was purified over a sucrose gradient. Virus
was titrated on Tk2 cells plated in 6-well plates. Cells
ere stained 2 days after infection with crystal violet to
isualize viral plaques.
Adenovirus and adenovirus recombinants were prop-
gated on the E1-transfected 293 cell line. Semiconfluent
onolayers of cells were infected with 0.1 PFU/cell of
s
airus. Cells were harvested after 3 days and freeze/
hawed three times. Cell debris was removed by centrif-
gation at 2000 rpm for 30 min. For some experiments
irus was purified through a cesium chloride gradient.
irus was titrated on 293 cell monolayers. Cells plated in
-well plates were infected with serial dilutions of virus
ontaining medium. The following day cells were over-
aid with agarose. Viral plaques were counted 4–5 days
ater.
accination studies
Recombinant vaccinia virus or adenovirus was given
t 1–2 3 107 PFU sc prior to challenge with tumor cells.
Vaccinia virus recombinants expressing the rabies virus
glycoprotein (VRG) and adenovirus recombinants ex-
pressing the rabies virus glycoprotein (Adrab.gp) were
used as controls. None of the immunized mice exhibited
any clinically apparent side effects after inoculation with
any of the vaccines.
Challenge of mice
Mice were challenged 2–3 weeks after immunization
with tumor cells given sc or intravenously. In most ex-
periments, t(10)1rasE7E6 cells were given at 3 3 104
cells per mouse and TC-1 cells were injected at 2–20 3
105 cells/mouse. In some experiments mice were chal-
enged an additional time using 5–10 3 105
t(10)1rasE7E6 cells or 1 3 106 TC-1 cells. Mice were
hecked after tumor cell challenge three times a week.
hey were scored as tumor bearing when the subcuta-
eous growth exceeded 2 mm in diameter. Mice were
uthanized once tumors reached a size of 1–2 cm in
iameter.
ntibody depletion studies
In vivo depletion of specific T cell subsets was accom-
lished by injecting mice intraperitoneally (ip) with a rat
Abs specific for mouse CD4 (GK1.5, ATCC) or CD8
53.6.7, ATCC) using 0.2-ml aliquots of a 1:10 dilution of
ntibody derived from the ascitic fluid of SCID mice
njected with hybridoma cells. The antibodies were in-
ected on Days 24, 21, 11, 14, and 18 relative to tumor
ell injection (Day 0). Preliminary experiments based on
taining of peripheral blood lymphocytes with FITC-la-
eled antibodies to CD4 or CD8 confirmed that this
reatment resulted in .95% reduction of the appropriate
cell subset (data not shown).
n vitro expansion of splenocytes
Splenocytes were harvested 7 days after immunization
nd cultured at 6 3 106 cells in 1.6 ml of DMEM (with 2%
BS, HEPES buffer, 10 mm 2-mercaptoethanol, nones-
ential amino acids, glutamine, sodium pyruvate, and
ntibiotics). Adenoviral recombinants were added at 0.1
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159VACCINES TO E6 AND E7 ANTIGENSPFU per cell. Cells were tested for cytolytic activity 5
days later. Splenocytes from immune mice were stimu-
lated in vitro under limiting dilution conditions at varied
concentrations in 96-well U-bottom microtiter plate wells
in DMEM supplemented with 10% FBS, using 24 wells for
each responder cell dilution. Cells were cultured with 106
irradiated (1700 rad) syngeneic splenocytes from naive
mice that had been infected with 0.1 PFU/cell of an
adenoviral recombinant. Rat concanavalin A supernatant
was added to a final concentration of 25%. Wells without
responder cells were set up as controls. Cells were
tested after a 7-day culture period.
51Cr-release assay
Cells stimulated in vitro under bulk culture conditions
ere tested at varied effector to target cell ratios on 5 3
03 51Cr-labeled target cells. Target cells were either
unmodified or infected with 10 PFU/cell of a viral recom-
binant 2 h (vaccinia virus) or 18 h (adenovirus) before
addition of 51Cr. RMAS cells were cultured overnight in
edium supplemented with 2% FBS at room tempera-
ure; they were subsequently incubated for 18 h at 37°C
ith 50 mg/ml of peptide in serum-free medium. Target
ells were cocultured with in vitro-expanded lympho-
ytes in 200 ml of DMEM supplemented with 10% FBS in
-bottom microtiter plate wells for 5 h. Wells which re-
eived target cells and medium were used to determine
pontaneous lysis; target cells were incubated in 1%
DS to assess maximal lysis. Supernatants were har-
ested and counted in a g-counter. Percentage of spe-
cific lysis was calculated as described (Ertl et al., 1984).
Cells restimulated under limiting dilution conditions were
tested on 2 3 103 target cells in a 6-h assay basically as
described above. Cells of each well were mixed thor-
oughly and then split equally into two V-bottom plate
wells to determine antigen-specific lysis as well as non-
specific cytolytic activity on target cells not expressing
the antigen under interrogation. The mean 51Cr release of
arget cells cocultured with cells from the 24 control
ells (without responder cells) 13 standard deviations
SD) of this mean was calculated. Wells that result in 51Cr
elease above this mean 13 SD were considered as
ositive. The frequency of antigen-specific responder
ells was calculated as described (Ertl and Finberg,
984).
ntracellular cytokine staining
Groups of C57Bl/6 mice were immunized with 1–2 3
07 PFU of AdE7 or VacE7 virus given sc. Splenocytes
were harvested 7 days later and incubated with or with-
out peptides (2.5 mg/ml) for 5 h in 96-well U-bottom
plates (Costar, Cambridge, MA) at a concentration of 106
cells/well in a volume of 200 ml in complete DMEM
medium supplemented with 50 units/ml of human recom-
binant IL-2 and 1 ml/ml of Brefeldin A (Golgistop, Pharm-ingen, La Jolla, CA). After 5 h, the cells were washed
once and surface-stained with phycoerythrin (PE)-conju-
gated rat anti-mouse CD8 antibody (Boehringer Mann-
heim) followed by fixation/permeabilization (Cytofix/Cyto-
perm, Pharmingen, LaJolla, CA) and intracellular staining
for IFN-g (FITC-conjugated rat anti-mouse IFN-g, Pharm-
ingen) according to the manufacturer’s instructions.
Flow cytometry and data analysis
Single cell suspensions were acquired and analyzed
on a Coulter flow cytometer. Thresholds for positive and
negative cells were set up on the basis of an isotype
control antibody (FITC-rat IgG1 isotype immunoglobulin,
Pharmingen). Unstimulated cells or cells incubated with
an irrelevant peptide (VMCYSPPL) were used to assess
spontaneous INF-g production.
tatistical analysis
Protection experiments were analyzed by Wilcoxon
igned rank comparing the time (days after challenge) of
he appearance of visible tumors in sham-vaccinated
ice with that in mice vaccinated with a vaccine to E6 or
7.
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